Iclusig (ponatinib) is a kinase inhibitor indicated for the: Treatment of adult patients with chronic phase, accelerated phase Chronic Myeloid Leukaemia (CML) who resistance or intolerance to tyrosine kinase inhibitor (dasatinib or nilotinib); Treatment of adult patients with T3151 positive CML (chronic phase, accelerated phase).
Limitation of use: Iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase CML.